MPM

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Bangladesh Technical Education Board, Takeda Pharmaceutical Company, MPM, Schering-Plough, Science Publishing Group, Hoechst AG, Research and development, NIH, Moderna, PureTech Health, Drug development, Bristol Myers Squibb, Doctor of Philosophy, Renegade, University, Partner, RNA, Therapy, Patient, Protein, Takeda Oncology, Development, Immune system, Pharmaceutical industry

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Firefly Bio Debuts With $94 Million Series A Financing

Retrieved on: 
Thursday, February 15, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Therapy, Versant, Merck, MPM, Nobel Prize, Collateral damage, Therapeutic index, Cell, Eli Lilly and Company, ADC, Genentech, Protein, Nobel Prize in Chemistry, Novartis, CSO, Firefly, FireLink, Cancer, Fine chemical

Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.

Key Points: 
  • Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.
  • Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs).
  • Firefly was incubated in close collaboration with scientists at Versant’s Ridgeline Discovery Engine in the Basel Technology Park.
  • “At Firefly, we’ve assembled a unique talent base and platform to significantly advance this promising field,” said Jerel Davis, Ph.D., Managing Director at Versant and a Firefly board member.

NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management

Retrieved on: 
Wednesday, February 14, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, MPM, Doctor of Philosophy, Immunotherapy, Extension, Dana–Farber Cancer Institute, Series, WTT, Bayer, Patient, Cancer, Pharmaceutical industry

NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing.

Key Points: 
  • NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing.
  • The Extension was led by existing investor Catalio Capital Management, and as part of the financing, R. Jacob Vogelstein, PhD, has joined the NextPoint Board of Directors.
  • Catalio is joined by other existing investors including MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Dana-Farber Cancer Institute’s Binney Street Capital and NextPoint founder Gordon Freeman, PhD.
  • Along with Catalio, new investors Arkin Bio-Capital and WTT investment Ltd were the largest participants in this fundraising.

NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Public, Growth, Booz Allen Hamilton, Harvard Business School, Therapy, Duke University, Patient, MBA, MPM, Drug development, PD-1, Doctor of Philosophy, Detlev, Cancer, Medicare, Pharmaceutical industry

NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Ivan Cheung as Chief Executive Officer (CEO) and to the Board of Directors.

Key Points: 
  • NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Ivan Cheung as Chief Executive Officer (CEO) and to the Board of Directors.
  • Mr. Cheung brings 25 years of drug development, approval and product launch achievements, and organizational leadership experience to NextPoint, most recently serving as Eisai’s U.S. CEO.
  • With his appointment, NextPoint aims to deliver breakthrough clinical outcomes from precision immuno-oncology therapeutics targeting the HHLA2 checkpoint axis and create additional modalities leveraging HHLA2 as a novel tumor antigen.
  • Under Dr. Biniszkiewicz’s leadership, NextPoint raised Series A and B funding and was transformed into a clinical-stage company.

AHN Allegheny General Hospital Achieves Prestigious Magnet® Designation for Nursing Excellence

Retrieved on: 
Friday, January 19, 2024
Magnet, AHN, Organ transplantation, General Hospital, Patient, Commission, Nursing, Allegheny General Hospital, Professional, Hospital, Trauma, MD, RN, BSN, Health, Culture, Medicine, Neuroscience, AGH, Allegheny Health Network, Doctor of Philosophy, Organization, MPM, ANCC, Research

PITTSBURGH, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.

Key Points: 
  • Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.
  • PITTSBURGH, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.
  • This Magnet designation is a reflection of the tireless dedication and exceptional nursing skills of our team at Allegheny General Hospital.
  • It is now the fourth AHN hospital to receive the Magnet designation, part of the network's ongoing campaign to transform the practice of nursing and sustain a culture of nursing excellence and innovation.

Labaton Sucharow LLP Announces Notice of Pendency and Proposed Stockholder Class Action Settlement to all Record Holders and Beneficial Owners of MPM Holdings Inc. Common Stock as of May 15, 2019

Retrieved on: 
Monday, January 8, 2024
Class Action Lawsuit, Professional Services, Legal, Compromise, Justice Center, Eligibility, Judgement, Agreement, Class, Mergers and acquisitions, Effective date, CLASS, Notice, ARE, MPM, Settlement, Episcopal conference, Defendant, Hearing, Prejudice

YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

Key Points: 
  • YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • The proposed Settlement, if approved, will resolve the Class Claims asserted in the Action, and the Class Claims will be dismissed with prejudice.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Settlement Administrator or Plaintiff’s Counsel.
  • Requests for the Notice should be made to the Settlement Administrator:
    Inquiries, other than requests for the Notice, should be made to Plaintiff’s Counsel:

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Retrieved on: 
Wednesday, December 27, 2023
Patient, DCR, Immunotherapy, National Cancer Institute, Rated R, Neoplasm, Survival, RECIST, GPS, CD8, Male, Standard of care, Progression-free survival, Trial of the century, Nivolumab, WT1, MPM, SLS, Combination, OS, PFS, Female, Pharmaceutical industry

NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced follow-up clinical/immune-response data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with the checkpoint inhibitor nivolumab (Opdivo®) in patients with refractory/relapsed malignant pleural mesothelioma (MPM).

Key Points: 
  • Nine out of ten patients (90%) had sufficient samples collected to be analyzed for GPS-specific immune response.
  • All enrolled patients had either received and progressed with or were refractory to frontline pemetrexed-based chemotherapy.
  • Additional analyses for the correlation of immune response and survival benefit were performed.
  • Among the nine evaluable patients, four patients had a CD4+ immune response (44.4%) and three patients had a CD8+ immune response (33.3%) to GPS.

Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma

Retrieved on: 
Friday, November 17, 2023
SAN, Chemistry, Food, BLA, Pemetrexed, Patient, FDA, Medical Affairs Bureau, MPM, Mesothelioma, Biologics license application, Pharmaceutical industry

The rolling submission process allows for the submission of individual modules of the BLA as they are completed, which can streamline the regulatory review process and may expedite the potential approval timeline.

Key Points: 
  • The rolling submission process allows for the submission of individual modules of the BLA as they are completed, which can streamline the regulatory review process and may expedite the potential approval timeline.
  • Dr. John Bomalaski, Executive Vice President of Medical Affairs at Polaris Group, commented, "Our clinical trials have demonstrated promising results, with ADI-PEG 20 showing statistically significant potential to address the medical needs of patients with malignant pleural mesothelioma.
  • Howard Chen, CEO and Chairman of Polaris Group, added, "We are fully committed to addressing the urgent medical needs of patients facing malignant pleural mesothelioma.
  • Today’s submission brings us one step closer to expanding treatment options for patients impacted by MPM in the U.S.

MP Machinery and Testing Provides Advanced Testing Services for the US Advanced Nuclear Reactor Initiative

Retrieved on: 
Tuesday, December 12, 2023
Avista Capital Partners, Power plant engineering, Capital, Charpy, NRC, MP, MPM, Temperature, Light-water reactor, LWR, Uranium mining

STATE COLLEGE, Pa., Dec. 12, 2023 /PRNewswire/ -- MP Machinery and Testing ("MPM"), a Praesidian Capital portfolio company and a global leader in advanced testing and test development is providing advanced testing services for the US advanced nuclear reactor initiative.

Key Points: 
  • STATE COLLEGE, Pa., Dec. 12, 2023 /PRNewswire/ -- MP Machinery and Testing ("MPM"), a Praesidian Capital portfolio company and a global leader in advanced testing and test development is providing advanced testing services for the US advanced nuclear reactor initiative.
  • The company not only provides a broad range of testing services but is also a manufacturer of testing and thermal conditioning equipment.
  • MPM's LWR nuclear hot cells can also be easily adapted for post-irradiation machining and testing of highly irradiated advanced reactor materials.
  • "MPM customers and competitor testing laboratories routinely come to MPM for assistance in non-standard testing applications," said Tom Duffy, Praesidian Capital Partner.

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023
JAK1, NMPA, Patient, American College of Rheumatology, Bayer, SUA, Neoplasm, Cataract, Therapy, URAT1, MBA, Cancer, Health care, Inflammation, Fabry disease, Safety, Toxicity, IND, SHP2, USD, Strong, Letter, Woman, EA Phenomic, Pharmacokinetics, VBI, HER2, MPM, Antibody, GCS, GEJ, Boehringer, Research, Plasma, Boehringer Ingelheim, Clinical trial, Investment, MaRS Discovery District, FDA, American College, Phase II, Clostridial necrotizing enteritis, Selective, MPH, ACR, EGFR, Pharmaceutical industry, Astellas Pharma, Phase, Deka, Facet joint arthrosis

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.